Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | APAF1 | O14727 | 2/20 | 0.77 |
| ▸ | CASP3 | P42574 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.77 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.77 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MDH2 | P40926 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | SNCA | P37840 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14938439 | 0.89 | MEN1 (0.71) | MEN1KMT2AAPAF1CASP3GAA | |
| SCHEMBL2580937 | 0.87 | KMT2A (1.00) | MEN1KMT2AAPAF1CASP3GAA | |
| SCHEMBL15627434 | 0.83 | MEN1 (0.70) | MEN1KMT2AAPAF1CASP3GAA | |
| SCHEMBL15620249 | 0.82 | MEN1 (0.69) | MEN1KMT2AAPAF1CASP3GAA | |
| SCHEMBL31399122 | 0.81 | L3MBTL1 (0.58) | MEN1KMT2AAPAF1CASP3GAA | |
| SCHEMBL25557092 | 0.81 | L3MBTL1 (0.58) | MEN1KMT2AAPAF1CASP3GAA | |
| SCHEMBL30100689 | 0.80 | POLB (0.71) | MEN1KMT2AAPAF1CASP3GAA | |
| SCHEMBL4328336 | 0.80 | POLB (0.71) | MEN1KMT2AAPAF1CASP3GAA | |
| SCHEMBL30100692 | 0.80 | POLB (0.71) | MEN1KMT2AAPAF1CASP3GAA | |
| SCHEMBL1185454 | 0.79 | MEN1 (0.55) | MEN1KMT2AAPAF1CASP3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673347-B1 | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2164830-B1 | PROCESS FOR THE PREPARATION OF DIBENZO [B,D]AZEPIN-6-ONE DERIVATIVE | HOFFMANN LA ROCHE (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-7579464-B2 | Process for preparation of enantiomerically pure compounds | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579464-B2 | Process for preparation of enantiomerically pure compounds | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579464-B2 | Process for preparation of enantiomerically pure compounds | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1711470-B1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-20080293933-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293933-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293933-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2008-11-27 | — | — | US | disclosed |
| US-7166587-B2 | Carbamic acid alkyl ester derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7160875-B2 | Malonamide derivatives | HOFFMANN-LA RACHE INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1711470-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| EP-1673347-A1 | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS | F. Hoffman-la Roche AG (CH) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040126-A1 | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050075327-A1 | Carbamic acid alkyl ester derivatives | HOFFMAN-LA ROCHE INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005023772-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075327-A1 | Carbamic acid alkyl ester derivatives | BCHE, CHRM1, ADCY7 | MEN1 1340/4885KMT2A 2212/4885APAF1 3047/4885 |
| US-20080293933-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE COMPOUNDS | BACE1, BACE2, BCHE | MEN1 260/4885KMT2A 3051/4885APAF1 1225/4885 |
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | BACE1, BACE2, APP | MEN1 1679/4885KMT2A 3495/4885APAF1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.